How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Blood Banking IVD Market
- By Product Type: Blood Grouping Reagents, Antibody Screening and Identification Reagents, Nucleic Acid Testing (NAT) Kits, Serological Testing Kits, Blood Typing Instruments
- By Technology: Immunohematology Testing, Molecular Diagnostics, Enzyme-Linked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Flow Cytometry
- By End User: Hospital Blood Banks, Independent Blood Banks, Diagnostic Laboratories, Research Institutes, Plasma Centers
- By Application: Blood Grouping and Typing, Infectious Disease Screening, Compatibility Testing, Quality Control Testing, Donor Screening
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Blood Grouping Reagents leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Blood Banking IVD Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Technology 5
End User 5
Application 5
Companies profiled
Grifols S.A.
Ortho Clinical Diagnostics (a part of Quidel Corporation)
Bio-Rad Laboratories Inc.
Terumo Corporation
Fresenius Kabi AG
Haemonetics Corporation
Sartorius AG
Macopharma
Becton
Dickinson and Company (BD)
Immucor Inc.
Orgenium Laboratories Oy
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Grifols S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Ortho Clinical Diagnostics (a part of Quidel Corporation)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Bio-Rad Laboratories Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Fresenius Kabi AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Haemonetics Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Macopharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Immucor Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Orgenium Laboratories Oy
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →MacoPharma Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Luminex Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Diagast
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Helena Laboratories
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →
Global · 2025–2033
$5,424M by 2033 · 9.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Blood Grouping Reagents50.1
- Antibody Screening and Identification Reagents11.3
- Nucleic Acid Testing (NAT) Kits15.6
- Serological Testing Kits15.1
- Blood Typing Instruments7.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$854.5M → $1,624M · 8.4%
Europe$595.6M → $1,301M · 10.3%
Asia Pacific$543.8M → $1,070M · 8.8%
Latin America$336.6M → $706.8M · 9.7%
Middle East and Africa$258.9M → $497.1M · 8.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.632026
9.652027
9.652028
9.682029
9.692030
9.702031
9.712032
9.722033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Grifols S.A.16.3
- Ortho Clinical Diagnostics (a part of Quidel Corporation)24.2
- Bio-Rad Laboratories Inc.5.4
- Terumo Corporation11.0
- Fresenius Kabi AG6.8
- Haemonetics Corporation8.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type19.6%
Technology18.5%
End User29.9%
Application32.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.2
- Europe25.0
- Asia Pacific20.6
- Latin America13.6
- Middle East and Africa9.6
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Grifols S.A. | 91 | 82 | 99 | 80 | 76 | 94 | 87 |
| Ortho Clinical Diagnostics (a part of Quidel Corporation) | 69 | 90 | 90 | 83 | 85 | 91 | 85 |
| Bio-Rad Laboratories Inc. | 68 | 70 | 87 | 80 | 80 | 66 | 75 |
| Terumo Corporation | 80 | 60 | 72 | 72 | 59 | 63 | 68 |
| Fresenius Kabi AG | 57 | 63 | 63 | 61 | 61 | 57 | 60 |
| Haemonetics Corporation | 66 | 51 | 64 | 67 | 68 | 59 | 63 |
| Sartorius AG | 62 | 60 | 45 | 64 | 56 | 64 | 59 |
| Macopharma | 59 | 39 | 57 | 42 | 44 | 51 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Grifols S.A.
- Ortho Clinical Diagnostics (a part of Quidel Corporation)
- Bio-Rad Laboratories Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Grifols S.A. | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Ortho Clinical Diagnostics (a part of Quidel Corporation) | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Bio-Rad Laboratories Inc. | − | − | ✓ | ◐ | ◐ | − |
| Terumo Corporation | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Fresenius Kabi AG | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Haemonetics Corporation | ✓ | ◐ | ◐ | ◐ | ◐ | − |
| Sartorius AG | − | − | − | ◐ | − | ◐ |
| Macopharma | ◐ | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Grifols S.A.87
2Ortho Clinical Diagnostics (a part of Quidel Corporation)85
3Bio-Rad Laboratories Inc.75
4Terumo Corporation68
5Haemonetics Corporation63
6Fresenius Kabi AG60
7Sartorius AG59
8Macopharma49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Grifols S.A.Ortho Clinical Diagnostics (a part of Quidel Corporation)
Challenger2
Strong scale, closing on the leaders.
Bio-Rad Laboratories Inc.Terumo Corporation
Contender3
Focused players with pockets of strength.
Fresenius Kabi AGHaemonetics CorporationSartorius AG
Niche1
Specialists in a single segment or region.
Macopharma
Go-to-market strategy
Land Product Type in North America, then scale across Blood Banking IVD Market — a $379M beachhead inside a $5.38B market.
Beachhead (SOM)$379Mobtainable near-term
Serviceable (SAM)$2.03Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Blood Grouping Reagents
Best fit — highest urgency & budget in Product Type.
Economic buyer77 fit
Antibody Screening and Identification Reagents
Strong fit — clear ROI and a fast path to value.
End user65 fit
Nucleic Acid Testing (NAT) Kits
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Blood Banking IVD Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified22%
Evaluation13%
Closed-won8%
$13.7KCAC
$67KLTV
4.9:1LTV : CAC
< 2 moCAC payback
Investment thesis
Blood Banking IVD Market is a high-growth opportunity — $2.47B by 2033, compounding at 10.4%.
TAM · 2025$1.12Btoday
TAM · 2033$2.47Bforecast
CAGR10.4%2027–2033
Cumulative$15.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.47BTotal addressable market
SAM$955MServiceable available market
SOM$170MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.4% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.47BLarge & growingTAM by 2033 at 10.4% CAGR
$955MServiceable nowreachable with today’s model
$170MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.92BBear6.8% CAGR
$2.47BBase10.4% CAGR
$3.16BBull13.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Blood Banking IVD Market — a $3.76B market by 2033. Plan: grow share from 6.8% to 14.5%.
Market size · 2033$3.76Btotal addressable
Market CAGR4.1%2027–2033
Target share14.5%from 6.8% today
Revenue ambition$546Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 14.5% | At risk |
| Revenue | $236M | $546M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 31.3% | 44.5% | Behind |
| Customer retention | 91.1% | 96.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Technology capability
A defensible second engine — invest in Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $61M capacity & capability investment
- Greenlight bolt-on M&A in Technology
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentOn track
Sales deck · value proposition
Win the Blood Banking IVD Market conversation — a $5.74B market you can size, segment and defend in minutes.
Market size · 2033$5.74Btotal opportunity
Growth11.5%CAGR to 2033
Addressable buyers1,427+accounts in scope
Typical ROI4.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.8×return on cost, year one
< 2 mopayback period
$82K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Grifols S.A.Ortho Clinical Diagnostics (a part of Quidel Corporation)Bio-Rad Laboratories Inc.Terumo CorporationFresenius Kabi AGHaemonetics CorporationSartorius AGMacopharma+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Blood Banking IVD Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Blood Banking IVD Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Blood Biochemical Examination Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportBlood Cancer Diagnostics Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportBlood Card Centrifuge Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBlood Cell Analysis Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBlood Coagulation Analysis Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportBlood Coagulation Factors Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportBlood Coagulation Test Analyzer Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportBlood Collecting Vehicles Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportBlood Collection Devices Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportBlood Collection Equipment Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBlood Collection Manager Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportBlood Collection Products for Veterinary Use Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.